This week two start-ups joined the Creation House program that provides labs, offices, business development and funding for up to DKK 10M per company over a period of 18 months.

The companies are currently moving their activities from both labs and offices to the BII facilities in the center of Copenhagen to be part of the start-up environment and close to the experts and networks that BII provides.

InProTher treats cancer by targeting tumor viruses within the human genome. The company has pre-clinical proof of concept for broad and curative cancer targeting and synergy with immune checkpoint inhibitors. InProTher’s research is based upon research by Associate Professor Peter Johannes Holst and colleagues plus international collaborators. He leads the start-up as the CSO alongside Nicolaj Højer Nielsen who is the CFO.
Follow InProTher on LinkedIn and visit their webpage.

Kariya Pharmaceuticals is developing a first-in-class treatment to slow the progression of Parkinson’s disease. The technology is based on the neuroprotective effects of incretins, where clinical proof-of-concept is well established on patients diagnosed with Parkinson’s disease. Over the next 18 months, Kariya will initiate and complete IND-enabling studies and advance their lead program to human trials.
The team consists of three founders: CEO Ian Laquian, CSO Christian Hölscher and CDO Mikael Thomsen.
Follow Kariya on LinkedIn and visit their webpage.

Do you want to join the two start-ups in the Creation House program with funding of up to DKK 10M? BioInnovation Institute is currently looking for start-ups. Apply here.

More news from BII
Martin Bonde: “Be first or best in class – or forget about it”